EMA streamlines CAT activities
This article was originally published in Scrip
Executive Summary
As part of its drive to improve its efficiency and optimise the use of expertise on-hand, the European Medicines Agency (EMA) has replaced the activities of the two working parties of its Committee for Advanced Therapies (CAT) – the Cell-based Products Working Party (CPWP) and the Gene Therapy Working Party (GTWP) - with ad-hoc drafting groups.